FY2025 · ended Dec 31, 2025 · Revenue $65,343, -70.0% YoY · Filed Mar 12, 2026
Inovio Pharmaceuticals, Inc. (INO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $65,343 and a net loss of $84.9 million. Free cash flow was -$88.9 million. As of Jun 30, 2026 it held $36.7 million in cash and investments and $8.0 million in total debt.
Revenue (TTM)
$0
-100.0% vs year-ago TTM
Net income (TTM)
$-67.43M
+23.2% vs year-ago TTM
Operating cash flow (TTM)
$-80.58M
+15.0% vs year-ago TTM
Free cash flow (TTM)
$-80.78M
+14.9% vs year-ago TTM
EPS (TTM)
$-1.04
+60.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
69.09M
+88.4% vs prior year
Net cash
$28.67M
as of Jun 30, 2026
Operating margin
-132871.3%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Plymouth Meeting, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1055726
- Former names
- INOVIO BIOMEDICAL CORP (until May 11, 2010); GENETRONICS BIOMEDICAL CORP (until Apr 1, 2005); GENETRONICS BIOMEDICAL LTD (until Aug 3, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $65,343 | $217,756 | $832,010 | $10.3M | $1.8M |
| Operating income | -$86.8M | -$112.4M | -$143.9M | -$267.6M | -$301.2M |
| Net income | -$84.9M | -$107.3M | -$135.1M | -$279.8M | -$303.7M |
| Diluted EPS | -$1.81 | -$3.95 | -$6.09 | -$14.07 | -$17.45 |
| Operating cash flow | -$88.6M | -$104.1M | -$124.4M | -$216.2M | -$215.7M |
| Free cash flow | -$88.9M | -$104.6M | -$124.7M | -$217.2M | -$216.9M |
| Total assets | $74.3M | $113.2M | $171.0M | $348.5M | $495.9M |
| Total liabilities | $50.2M | $44.7M | $53.6M | $126.2M | $96.3M |
| Stockholders' equity | $24.1M | $68.5M | $117.3M | $222.4M | $399.7M |
| Cash and investments | $58.5M | $94.1M | $145.3M | $253.0M | $401.3M |
| Total debt | $9.4M | $11.9M | $13.4M | $15.5M | $18.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 31, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
All 1000 Inovio Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.